Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis

Experimental Parasitology

Volumn 127, Issue 2, 2011, Pages 376-381

  Sane, Shraddha A ^a   Shakya, Nishi ^a   Gupta, Suman ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Combination therapy; Hamsters; Leishmania donovani; LTT; Miltefosine; Paromomycin; Phagocytosis; Picroliv; VL

Indexed keywords

HYDROGEN PEROXIDE; KUTKIN; MILTEFOSINE; PAROMOMYCIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAMSTER; IMMUNOMODULATION; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL PROLIFERATION; CINNAMATES; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLYCOSIDES; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LYMPHOCYTES; MALE; MESOCRICETUS; PAROMOMYCIN; PHAGOCYTOSIS; PHOSPHORYLCHOLINE; RANDOM ALLOCATION; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; VANILLIC ACID;

CRICETINAE; LEISHMANIA DONOVANI; PICRORHIZA KURROOA;

EID: 78751584788     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2010.09.003     Document Type: Article

References (34)

1. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., Lopez-Velez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus co-infection the first 10years. Clinical Microbiology Reviews 1997, 10:298-319.
2. Arevalo I., Ward B., Miller R., Meng T.C., Najar E., Alvarez E., Matlashewski G., Llanos-Cuentas A. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod immunomodulator. Clinical Infectious Diseases 2001, 33:1847-1851.
3. Berhe N., Wolday D., Hailu A., Abraham Y., Ali A., Gebre Michael T., Dasjeux P., Sonnerborg A., Akuffo H., Britton S. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999, 13:1921-1925.
4. Bern C., Adler-Moore J., Berenguer J., et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases 2006, 43:917-924.
5. Bhatnagar S., Guru P.Y., Katiyar J.C., et al. Exploration of antileishmanial activity in heterocycles results of their in vivo & in vitro bioevaluations. Indian Journal of Medical Research 1989, 89:439-444.
6. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine & International Health 2001, 6:928-934.
7. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Diseases 1999, 179:1485-1494.
8. Chander R., Kapoor N.K., Dhawan B.N. Picroliv affects gamma-glutamyl cycle in liver and brain of Mastomys natalensis infected with Plasmodium berghei. Indian Journal of Experimental Biology 1994, 32:324-327.
9. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., Alvar J., Boelaer M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nature Reviews Microbiology 2007, 5:873-882.
10. Croft S., Neal R., Pendergast W., Chan J. The activity of alkyl phosphocholines and related derivates against Leishmania donovani. Biochemical Pharmacology 1987, 36:2633-2636.
11. Davidson R.N., den Boer M., Ritmeijer K. Paromomycin. Transactions of Royal Society of Tropical Medicine & Hygiene 2009, 103:653-660.
12. Dwivedi Y., Rastogi R., Garg N.K., Dhawan B.N. Picroliv and its components kutkoside and picroside I protect liver against galactosamine-induced damage in rats. Pharmacology and Toxicology 1992, 71:383-387.
13. Gupta S., Ramesh, Sharma S.C., Shrivastava V.M.L. Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Tropica 2005, 94:41-47.
14. Gupta S., Srivastava V.M., Puri A., Pandey D., Haq W. Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis. Immunopharmacology and Immunotoxicology 2004, 26:425-434.
15. El-On Joseph, Bazarsky E., Sneir R. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod. Experimental Parasitology 2007, 116:156-162.
16. Melby P.C., Chandrasekar B., Zhao W., Coe J.E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. Journal of Immunology 2001, 166:1912-1920.
17. Murray H.W., Berman J.D., Wright S.D. Immunotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. Journal of Infectious Diseases 1988, 157:973-978.
18. Murray H.W., Oca M.J., Granger A.M., Schreiber R.D. Requirement for T cells and effects of lymphokines in successful chemotherapy for an intracellular infection: experimental visceral leishmaniasis. Journal of Clinical Investigation 1989, 83:1253-1257.
19. Pathak N., Khandelwal S. Comparative efficacy of piperine, curcumin and picroliv against Cd immunotoxicity in mice. Biometals 2008, 21:649-661.
20. Puri A., Saxena R.P., Guru P.Y., Kulshreshtha D.K., Saxena K.C., Dhawan B.N. Immunostimulant activity of picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, and its protective action against Leishmania donovani infection in hamsters. Planta Medica 1992, 58:528-532.
21. Puri A., Sahai R., Haq W., Zaidi A., Guru P.Y., Tripathi L.M., Srivastava V.M. Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster. International Immunopharmacology 2005, 5:937-946.
22. Ray A., Chaudhuri S.R., Majumdar B., Bandyopadhyay S.K. Antioxidant activity of ethanol extract of rhizome of Picrorhiza kurroa on indomethacin induced gastric ulcer during healing. Indian Journal of Clinical Biochemistry 2002, 17:44-51.
23. Saraswat B., Visen P.K., Patnaik G.K., Dhawan B.N. Anticholestatic effect of picroliv, active hepatoprotective principle of Picrorhiza kurrooa, against carbon tetrachloride induced cholestasis. Indian Journal of Experimental Biology 1993, 31:316-318.
24. Seifert K., Croft S.L. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrobial Agents and Chemotherapy 2006, 50:73-79.
25. Seth P., Sundar S.V., Seth R.K., Sidhu G.S., Sharma S.C., Kulshreshtha D.K., Maheshwari R.K. Picroliv modulates antioxidant status and down-regulates AP1 transcription factor after hemorrhage and resuscitation. Shock 2003, 19:203-213.
26. Sharma P., Raghavan S.A.V., Saini R., Dikshit M. Ascorbate-mediated enhancement of reactive oxygen species generation from polymorphonuclear leukocyte: modulatory effect of nitric oxide. Journal of Leukocyte Biology 2004, 75:1070-1078.
27. Shrivastava J.K., Misra A., Sharma P., Shrivastava B., Naik S., Dube A. Prophylactic potential of autoclaved Leishmania donovani with BCG against experimental visceral leishmaniasis. Parasitology 2003, 127:107-114.
28. Solgi G., Kariminia A., Abdi K., Darabi M., Ghareghozloo B. Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice. Korean Journal of Parasitology 2006, 44:55-61.
29. Sundar S., Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian Journal of Medical Research 2006, 123:345-352.
30. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. New England Journal of Medicine 2007, 356:2571-2581.
31. Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine & International Health 2001, 6:849-854.
32. Walrand S., Valeix S., Rodriguez C., Ligot C., Chassagne J., Vasson M.P. Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes. Clinica Chimica Acta 2003, 331:103-110.
33. Yadav N., Khandelwal S. Effect of picroliv on cadmium-induced hepatic and renal damage in the rat. Human Experimental Toxicology 2006, 25:1-11.
34. Yadav N., Khandelwal S. Effect of picroliv on cadmium-induced testicular damage in the rat. Food and Chemical Toxicology 2008, 46:494-501.